- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03771430
A Multidisciplinary Intervention in Total Knee Arthroplasty (MultiKnee)
A Multidisciplinary Intervention in Total Knee Arthroplasty - a Multicenter, Randomized Controlled Trial in OA Patients (The MultiKnee Trial)
Study Overview
Status
Intervention / Treatment
Detailed Description
The study is a multidisciplinary trial testing an intervention delivered by physiotherapists. Up to 20% of total knee arthroplasty (TKA) patients continue to experience moderate/severe pain 12 months after TKA. While physical therapy (PT) and cognitive-behavior therapy (CBT) have shown promise for improving outcomes, they have not been evaluated in combination or in patients at risk for chronic pain after TKA. This trial will evaluate PT+CBT combined, either as a substitute for or as a supplement to TKA for patients at risk for chronic pain after TKA.
Pilot/Feasibility study:
The study will include a feasibility/pilot study with 15 patients to be performed from November 2018. The intervention and study procedures may be modified based on results from the feasibility/pilot study.
Full scale Randomized Controlled Trial (RCT):
The full-scale RCT will include 282 patients scheduled for TKA. Patients will be randomly assigned to one of three groups: 1) non-surgical intervention (i.e., PT+CBT), 2) a combination of TKA with pre- and postoperative PT+CBT, or 3) A control group receiving TKA and usual care follow-up. Primary outcome: The Pain subscale from the KOOS. The intervention has the potential to improve outcomes for patients who currently obtain little benefit from standard TKA.
Cross-sectional observational study: Patients declining to participate in the RCT will be offered the option to participate in a separate cross-sectional study. The inclusion and exclusion criteria will be identical to the RCT. Patients who agree to participate in the cross-sectional study will complete the same baseline questionnaires as in the RCT and are asked about the reasons they did not want to participate in the RCT.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Maren Falch Lindberg, PhD
- Phone Number: +4794815762
- Email: mfli@lds.no
Study Contact Backup
- Name: Anners Lerdal, PhD
- Phone Number: +4795033144
- Email: anners.lerdal@medisin.uio.no
Study Locations
-
-
-
Bergen, Norway
- Recruiting
- Haukeland University Hospital - Kysthospitalet Hagevik
-
Contact:
- Kari Indrekvam, PhD
- Phone Number: +47913 32 899
- Email: kari.indrekvam@helse-bergen.no
-
Contact:
- Mona Badawy, PhD
- Phone Number: +4756565927
- Email: mona.badawy@helse-bergen.no
-
Sub-Investigator:
- Turid Rognsvåg, Msc
-
Principal Investigator:
- Mona Badawy, PhD
-
Oslo, Norway
- Recruiting
- Lovisenberg Diaconal Hospital
-
Contact:
- Maren F Lindberg, PhD
- Phone Number: +4794815762
- Email: m.k.f.lindberg@medisin.uio.no
-
Contact:
- Anners Lerdal, PhD
- Phone Number: 22358206
- Email: anners.lerdal@medisin.uio.no
-
Principal Investigator:
- Anners Lerdal, PhD
-
Principal Investigator:
- Arild Aamodt, PhD
-
Oslo, Norway
- Recruiting
- Martina Hansens Hospital
-
Contact:
- Stig Heir, PhD
-
Principal Investigator:
- Nina J Kise, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Scheduled for TKA for OA at Lovisenberg, Oslo; Martina Hansen, Bærum, or Coastal Hospital Hagevik, Bergen
- Age 18 - 79 years
- ASA grade 1-3
- KL grade 3 or 4
- BMI<40
- Able to read and write in Norwegian
Exclusion Criteria:
- Diagnosis of dementia or sero-positive rheumatic disease
- Previously undergone uni or patellofemoral prosthesis in the index knee
- Large axis deviation or instability requiring use of hinged implants
- Scheduled for unicompartmental arthroplasty or revision surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Non-surgical group
Osteoarthritis education, exercise and eCBT
|
Osteoarthritis Education
Online CBT (iCBT) (10 modules completed at home)
Other Names:
|
Experimental: Combined group
Total knee arthroplasty + osteoarthritis education, exercise and eCBT
|
Osteoarthritis Education
Online CBT (iCBT) (10 modules completed at home)
Other Names:
Standard total knee arthroplasty will be performed.
Other Names:
|
Active Comparator: Surgery only (standard care)
Total knee arthroplasty + standard physiotherapy
|
Standard total knee arthroplasty will be performed.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the knee injury and osteoarthritis score (KOOS) pain subscale
Time Frame: Before randomization, 12 months after treatment start. Also measured at 3, 6, and 24 months after treatment start.12 months after treatment start will be the primary outcome.
|
KOOS is a knee-specific, patient administered questionnaire developed to evaluate short- and long-term symptoms and functioning in subjects with knee injury and osteoarthritis. KOOS is validated for use in total knee arthroplasty and has been shown to be a valid, reliable and responsive measure. KOOS is a patient-administered questionnaire. The KOOS is a knee joint specific questionnaire with 42 items designed to assess patients' opinions about their difficulties with activity due to problems with their knees during the past week. The pain subscale of the KOOS consists of 9 items that assess frequency of pain and pain severity in different situations. Each of the 42 items carries equal weighting (0-4), with higher scores indicating better functioning. The pain subscale score will be transformed to a 0-100 scale, with 0 representing extreme knee problems and 100 representing no problems. |
Before randomization, 12 months after treatment start. Also measured at 3, 6, and 24 months after treatment start.12 months after treatment start will be the primary outcome.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Knee injury and osteoarthritis score (KOOS) subscores: Other symptoms, activities of daily living (ADL), function in sport and recreation, and knee-related quality of life (QOL)
Time Frame: Before randomization. 3, 6, 12 and 24 months following treatment start
|
KOOS is a knee-specific questionnaire developed to evaluate short- and long-term symptoms and functioning in subjects with knee injury and osteoarthritis. The KOOS is a knee joint specific questionnaire with 42 items designed to assess patients' opinions about their difficulties with activity due to problems with their knees during the past week. KOOS has 5 subscales: pain, other symptoms, activities of daily living (ADL), function in sport and recreation, and knee-related QOL. The KOOS has been validated for use in TKA and has been shown to be valid, reliable and responsive. Each of the 42 items carries equal weighting (0-4), with higher scores indicating better functioning. Each of the subscale scores are transformed to a 0-100 scale, with 0 representing extreme knee problems and 100 representing no problems. KOOS is a patient-administered questionnaire. |
Before randomization. 3, 6, 12 and 24 months following treatment start
|
The 30 second sit to stand test
Time Frame: Before treatment start. 3, 6, 12 and 24 months following treatment start
|
The 30-second sit to stand test will be used to assess functional lower extremity strength.
This test is performed using a chair of standard height without arms.
The participant is encouraged to complete as many full stands as possible within 30 seconds.
|
Before treatment start. 3, 6, 12 and 24 months following treatment start
|
Brief Pain inventory
Time Frame: Before randomization. 3, 6, 12 and 24 months following treatment start
|
The Brief Pain Inventory (BPI) will be used to measure pain (56).
The BPI is a brief patient-completed questionnaire that consists of four items that measure pain intensity (on an 11-point numeric rating scale from 0-10), seven questions on pain interference with functioning, a body map to localize the pain and one item on pain relief.
|
Before randomization. 3, 6, 12 and 24 months following treatment start
|
EuroQol-5D-5L
Time Frame: Before randomization. 3, 6, 12 and 24 months following treatment start
|
The widely used EuroQol-5 (EQ-5D-5L) will be used to measure health-related quality of life. The EQ5D-5L consists of two parts: A descriptive system (Mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and the EQ-VAS that record patients self-rated health on a visual analog scale that range from 0 - 100, higher levels indicate better self-rated health. The descriptive system can be converted to a single summary index number where lower levels indicate poorer health-related quality of life. |
Before randomization. 3, 6, 12 and 24 months following treatment start
|
The Forgotten Joint Score
Time Frame: Before randomization. 3, 6, 12 and 24 months following treatment start
|
The Forgotten Joint Score will be used to assess how natural the prosthesis feels after total knee arthroplasty.
The scoring system consists of 12 items that assess patients agreement with 12 statements, that range from 1 (never) to 5 (mostly).
The raw score is transformed to a 0-100 score and then reversed to obtain the final score.
A higher score indicate better outcome.
|
Before randomization. 3, 6, 12 and 24 months following treatment start
|
Pain Catastrophizing Scale
Time Frame: Before randomization. 3, 6, 12 and 24 months following treatment start
|
The Pain Catastrophizing scale (PCS) will be used to measure catastrophic thinking related to pain.
The scale consist of 13 items that range from 0 -4.
The PCS assesses three dimensions of catastrophizing (i.e., rumination (range 0-16), magnification (range: 0-12, helplessness (range 0 -24).
Higher scores indicate higher levels of catastrophic thinking related to pain.
A total score can be computed by summing responses to all 13 items.
PCS total scores range from 0-52.
Higher scores indicate higher levels of catastrophic thinking related to pain.
|
Before randomization. 3, 6, 12 and 24 months following treatment start
|
Patient-acceptable symptom state, perceived treatment failure.
Time Frame: At 3, 6, 12 and 24 months following treatment start.
|
Patient-acceptable symptom state will be measured by a single item question. The patient state wether they consider their knee function satisfactory or not (Yes/No). Perceived treatment failure will be measured by a single item question. The patient state whether their situation is so dissatisfying that they consider the treatment as a failure (Yes/No). |
At 3, 6, 12 and 24 months following treatment start.
|
Global perceived effect
Time Frame: At 3, 6, 12 and 24 months following treatment start.
|
The patient rate their level of knee problems compared to their condition before they started their treatment, by choosing on of seven statements that describe the level of improvement/worsening. The statements range from "better - an important improvement" - to "worse, an important worsening". |
At 3, 6, 12 and 24 months following treatment start.
|
Adverse events/serious adverse events
Time Frame: From treatment start until 24 months following treatment start.
|
All events reported by participant, physiotherapist or documented in the patient's hospital record.
|
From treatment start until 24 months following treatment start.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pittsburgh Sleep Quality Index
Time Frame: Before randomization. 3, 6, 12 and 24 months following treatment start
|
The Pittsburgh Sleep Quality index (PSQI) is a widely-used self-report measure of sleep disturbance during the past month.
The PSQI consists of 19 items that measures different aspects of sleep.
The 19 items produce 7 component scores (i.e., duration of sleep, sleep disturbance, sleep latency, day dysfunction due to sleepiness, sleep efficiency, overall sleep quality, need for sleep medications) each ranging from 0-3 where higher score indicate poorer sleep.
All component scores can be summarized to a global score that range from 0 to 21 where higher scores indicate poorer sleep quality.
The PSQI has good validity and reliability.
|
Before randomization. 3, 6, 12 and 24 months following treatment start
|
The Hospital Anxiety and Depression Scale
Time Frame: Before randomization. 3, 6, 12 and 24 months following treatment start
|
The Hospital Anxiety and Depression Scale (HADS) will be used to measure self-reported psychological distress (depression and anxiety).
The scale consists of 14 items, 7 on the depression subscale and 7 on the anxiety subscale.
The Norwegian version has excellent psychometric properties.
Each subscale range from 0-21 where higher scores indicate higher levels of anxiety or depression.
A total score (range 0 - 42) can be calculated from summarizing all the 14 items.
Higher scores indicate higher levels of anxiety/depression.
|
Before randomization. 3, 6, 12 and 24 months following treatment start
|
The Fear-Avoidance Belief Questionnaire
Time Frame: Before randomization. 3, 6, 12 and 24 months following treatment start
|
The Fear-Avoidance Belief Questionnaire (FABQ) will be used to measure pain-related fear of movement.
The instrument consists of 2 subscales, fear-avoidance beliefs for work, and fear-avoidance beliefs for physical activity (FABQ-PA).
Only the FABQ-PA subscale will be used in this study.
The FABQ-PA consists of 4 items where patients rate their agreement with 5 statements about pain and physical activity.
The FABQ-PA range from 0-24 and higher scores indicate higher levels of pain-related fear of movement.
|
Before randomization. 3, 6, 12 and 24 months following treatment start
|
Health Locus of Control Scale
Time Frame: Before randomization. 3, 12 and 24 months following treatment start
|
The Health Locus of Control Scale (HLCS) will be used to measure patients' anticipations between own health and disease behavior and consequences of the behavior.
The scale consists of 18 statements.
Patients rate their agreement on a 6 point likert scale ranging from disagrees completely to agrees completely.
Scoring: The scoring system consists of 3 subscales: The Internal Locus of Control, the Powerful Others Health Locus of Control, and the Chance Health Locus of control.
The scores are obtained by summing items for each subscale.
Higher scores indicate stronger agreement or inclination towards that particular subscale.
|
Before randomization. 3, 12 and 24 months following treatment start
|
Self-reported level of physical activity
Time Frame: Before randomization. 3, 6, 12 and 24 months following treatment start
|
Self-reported level of physical activity will be measured using two items from the Norwegian Hunt2 survey that assess frequency of light and hard physical activity, and the Stages of Change for physical activity.
The Stages of Change for physical activity assess patients' readiness for physical activity.
Patients rate their agreement with five different statements about physical activity.
|
Before randomization. 3, 6, 12 and 24 months following treatment start
|
The ActiGraph Professional single-axis accelerometer
Time Frame: Before treatment start. 6, 12 and 24 months following treatment start
|
The ActiGraph Professional single-axis accelerometer, a body worn sensor system to measure physical activity, will be used to measure time in sedentary and active positions, duration of activity and number of steps during walking
|
Before treatment start. 6, 12 and 24 months following treatment start
|
The 40 meters walk test
Time Frame: Before treatment start. 3, 6, 12 and 24 months following treatment start
|
The 40 meter walk test: The patient is instructed to walk 40 meter under timing.
|
Before treatment start. 3, 6, 12 and 24 months following treatment start
|
Stair Climb Test
Time Frame: Before treatment start. 3, 6, 12 and 24 months following treatment start
|
The Stair Climb Test will be used to measure ascending and descending stair activity, and lower body strength and balance, measured as a participants' time in seconds to ascend and descend a flight of stairs.
|
Before treatment start. 3, 6, 12 and 24 months following treatment start
|
Registry-based data on use of health care resources
Time Frame: From before randomization until 3, 6, 12 and 24 months after treatment start.
|
Use of health care resources will be measured using registry data from the KUHR-system (i.e., control and payment of reimbursements to health service providers), the Norwegian Patient Registry (NPR) FD Trygd social security database, the Norwegian Prescription Database and the Norwegian Arthroplasty registry.
All information will be anonymized and linked to each patient using a code number before analysis.
|
From before randomization until 3, 6, 12 and 24 months after treatment start.
|
Radiographs: weightbearing AP, lateral view, Rosenberg view and long leg weightbearing AP view (HKA)
Time Frame: Before treatment start, 12 months following treatment start.
|
X-rays including weightbearing AP, lateral view, Rosenberg view and long leg weightbearing AP view (HKA) weightbearing AP view (HKA).
OA severity grading will be performed according to the Kellgren-Lawrence grading system and cartilage thickness.
|
Before treatment start, 12 months following treatment start.
|
Screening and recruitment of patients (pilot study with 15 patients).
Time Frame: Baseline T1 before randomization
|
Number of patients undergoing screening, considered for inclusion, eligible for inclusion, consenting to participate and undergoing randomization
|
Baseline T1 before randomization
|
Adherence to the intervention (pilot study with 15 patients)
Time Frame: From treatment start until 12 weeks following treatment start.
|
Number of patients receiving the full dose of the intervention.
adverse events, recruitment, screening and randomization, retention in study/loss to follow-up.
|
From treatment start until 12 weeks following treatment start.
|
Acceptability of the intervention (pilot study with 15 patients)
Time Frame: From treatment start until 12 weeks following treatment start.
|
Number of patients feeling overwhelmed or burdened by the intervention.
Number of patients not completing the intervention due to feeling overwhelmed ro burdened by the intervention.
|
From treatment start until 12 weeks following treatment start.
|
Level of electronic health literacy
Time Frame: Before treatment start, 6 months after treatment start
|
The Electronic Health Literacy Questionnaire (e-HLQ) (44) will be used to measure patients level of electronic health literacy prior to, and six months following surgery.
In this study, 4 domains will be assessed: 1) using technology to process health information, 2) understanding of health concepts and language, 3) ability to actively engage with digital services, 4) motivated to engage with digital services.
The scores range 1-4, with high scores indicating high e-health literacy.
|
Before treatment start, 6 months after treatment start
|
Level of health literacy
Time Frame: Before treatment start, 6 months after treatment start
|
The International Health Literacy Population survey Questionnaire 2019-2021(HLS19-Q47) will be used to measure patients' level of health literacy prior to, and six months following surgery.
The original HLS-19-Q47 consist of 47 items.
In this study, 2 domains will be assessed: 1) Health promotion and 2) General health literacy.
|
Before treatment start, 6 months after treatment start
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anners Lerdal, PhD, Lovisenberg Diaconal Hospital, University of Oslo
- Principal Investigator: Arild Aamodt, PhD, Lovisenberg Diakonale Hospital
- Study Director: Maren F Lindberg, PhD, Lovisenberg Diakonale Hospital/University of Oslo
- Study Chair: Kari Indrekvam, PhD, Haukeland University Hospital - Kysthospitalet Hagevik/University of Bergen
- Study Chair: Stig Heir, PhD, Martina Hansens Hospital
Publications and helpful links
General Publications
- Lindberg MF, Aamodt A, Badawy M, Bergvad IB, Borchgrevink P, Furnes O, Gay C, Heir S, Holm I, Indrekvam K, Kise N, Lau B, Magnussen J, Nerhus TK, Rognsvag T, Rudsengen DE, Rustoen T, Skou ST, Stubberud J, Smastuen MS, Lerdal A. The effectiveness of exercise therapy and education plus cognitive behavioral therapy, alone or in combination with total knee arthroplasty in patients with knee osteoarthritis - study protocol for the MultiKnee trial. BMC Musculoskelet Disord. 2021 Dec 20;22(1):1054. doi: 10.1186/s12891-021-04924-z.
- Rognsvag T, Lindberg MF, Lerdal A, Stubberud J, Furnes O, Holm I, Indrekvam K, Lau B, Rudsengen D, Skou ST, Badawy M. Development of an internet-delivered cognitive behavioral therapy program for use in combination with exercise therapy and education by patients at increased risk of chronic pain following total knee arthroplasty. BMC Health Serv Res. 2021 Oct 25;21(1):1151. doi: 10.1186/s12913-021-07177-7.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MultiKnee Trial
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degenerative Joint Disease of Knee
-
Yooyoung Pharmaceutical Co., Ltd.Opera CRO, a TIGERMED Group CompanyNot yet recruitingOsteoarthritis, Knee | Degenerative Joint Disease of Knee
-
Lovisenberg Diakonale HospitalHaugesund Rheumatism HospitalRecruitingGonarthrosis; Primary | Degenerative Joint Disease of KneeNorway
-
MicroPort Orthopedics Inc.Active, not recruitingPost Market Clinical Follow-Up Study for EVOLUTION® BIOFOAM® Tibia and EVOLUTION® CS/CR Porous FemurKnee Osteoarthritis | Avascular Necrosis | Degenerative Joint Disease of Knee | Rheumatoid Arthritis of Knee | Correction of Functional Deformity | Traumatic Arthritis of KneeUnited States
-
Smith & Nephew, Inc.Active, not recruitingNon-inflammatory Degenerative Joint Disease (NIDJD) of the KneeUnited States, Italy, Poland
-
Mayo ClinicRecruitingOsteo Arthritis Knee | Degenerative Joint Disease of KneeUnited States
-
Limacorporate S.p.aRecruitingRheumatoid Arthritis | Osteoarthritis, Knee | Avascular Necrosis | Traumatic Arthritis | Degenerative Joint Disease of Knee | Deformity of KneeUnited States
-
Zimmer BiometWithdrawnOsteoarthritis | Traumatic Arthritis | Varus Deformity | Knee Pain Chronic | Degenerative Joint Disease of KneeUnited States
-
University of California, Los AngelesVarian Medical SystemsRecruitingKnee Osteoarthritis | Degenerative Joint Disease of KneeUnited States
-
Siddharth Padia, MDBoston Scientific CorporationCompletedKnee Osteoarthritis | Degenerative Joint Disease of KneeUnited States
-
Mary O'ConnorFlorida State University; University of Calgary; Georgia Institute of Technology and other collaboratorsCompletedOsteoarthritis | Degenerative Joint DiseaseUnited States
Clinical Trials on Osteoarthritis education, exercise and CBT
-
Joint AcademyLund UniversityCompleted
-
McMaster UniversityBoston University; University of British Columbia; University of MelbourneRecruiting
-
Lund UniversityCompletedOsteoarthritis | Patient Education as TopicSweden
-
University of CalgaryUniversity of British ColumbiaRecruitingOsteoarthritis | Osteoarthritis, Knee | Osteo Arthritis Knee | Osteoarthritis, HipCanada
-
US Department of Veterans AffairsCompleted
-
Shirley Ryan AbilityLabNorthwestern UniversityRecruitingArthritis | Joint Diseases | Musculoskeletal Diseases | Rheumatic Diseases | Osteoarthritis | Knee OsteoarthritisUnited States
-
Durham VA Medical CenterUnknownKnee Osteoarthritis
-
Istanbul Medipol University HospitalRecruitingOsteoarthritis, KneeTurkey
-
Seattle Children's HospitalJohns Hopkins University; Duke University; Vanderbilt University; University of... and other collaboratorsRecruitingScoliosis Idiopathic | Spondylolisthesis | Scoliosis; Adolescence | Kyphosis | Juvenile; Scoliosis | Scoliosis;CongenitalUnited States
-
Shirley Ryan AbilityLabNorthwestern University; Fitness Cubed Inc.RecruitingArthritis | Joint Diseases | Musculoskeletal Diseases | Rheumatic Diseases | Osteoarthritis | Knee OsteoarthritisUnited States